IDH1 and IDH2 Mutation Studies in 1473 Patients with Chronic-, Fibrotic- or Blast-Phase Essential Thrombocythemia, Polycythemia Vera or Myelofibrosis

IDH1 and IDH2 Mutation Studies in 1473 Patients with Chronic-, Fibrotic- or Blast-Phase Essential Thrombocythemia, Polycythemia Vera or Myelofibrosis

DSpace/Manakin Repository

IDH1 and IDH2 Mutation Studies in 1473 Patients with Chronic-, Fibrotic- or Blast-Phase Essential Thrombocythemia, Polycythemia Vera or Myelofibrosis

dc.contributor.author	Tefferi, A
dc.contributor.author	Lasho, T L
dc.contributor.author	Abdel-Wahab, O
dc.contributor.author	Guglielmelli, P
dc.contributor.author	Caramazza, D
dc.contributor.author	Pieri, L
dc.contributor.author	Finke, C M
dc.contributor.author	Kilpivaara, O
dc.contributor.author	Mai, M
dc.contributor.author	Gilliland, Dwight
dc.contributor.author	Pardanani, A
dc.contributor.author	Vannucchi, A M
dc.contributor.author	Patel, J.
dc.contributor.author	Wadleigh, Martha
dc.contributor.author	McClure, R. F.
dc.contributor.author	Levine, Robert A.
dc.date.accessioned	2011-09-21T14:51:19Z
dc.date.issued	2010
dc.identifier.citation	Tefferi, A., T. L. Lasho, O. Abdel-Wahab, P. Guglielmelli, J. Patel, D. Caramazza, L. Pieri, et al. 2010. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24(7): 1302-1309.	en_US
dc.identifier.issn	0887-6924	en_US
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:5136364
dc.description.abstract	In a multi-institutional collaborative project, 1473 patients with myeloproliferative neoplasms (MPN) were screened for isocitrate dehydrogenase 1 (IDH1)/IDH2 mutations: 594 essential thrombocythemia (ET), 421 polycythemia vera (PV), 312 primary myelofibrosis (PMF), 95 post-PV/ET MF and 51 blast-phase MPN. A total of 38 IDH mutations (18 IDH1-R132, 19 IDH2-R140 and 1 IDH2-R172) were detected: 5 (0.8%) ET, 8 (1.9%) PV, 13 (4.2%) PMF, 1 (1%) post-PV/ET MF and 11 (21.6%) blast-phase MPN (P<0.01). Mutant IDH was documented in the presence or absence of JAK2, MPL and TET2 mutations, with similar mutational frequencies. However, IDH-mutated patients were more likely to be nullizygous for JAK2 46/1 haplotype, especially in PMF (P=0.04), and less likely to display complex karyotype, in blast-phase disease (P<0.01). In chronic-phase PMF, JAK2 46/1 haplotype nullizygosity (P<0.01; hazard ratio (HR) 2.9, 95% confidence interval (CI) 1.7–5.2), but not IDH mutational status (P=0.55; HR 1.3, 95% CI 0.5–3.4), had an adverse effect on survival. This was confirmed by multivariable analysis. In contrast, in both blast-phase PMF (P=0.04) and blast-phase MPN (P=0.01), the presence of an IDH mutation predicted worse survival. The current study clarifies disease- and stage-specific IDH mutation incidence and prognostic relevance in MPN and provides additional evidence for the biological effect of distinct JAK2 haplotypes.	en_US
dc.language.iso	en_US	en_US
dc.publisher	Nature Publishing Group	en_US
dc.relation.isversionof	doi:10.1038/leu.2010.113	en_US
dc.relation.hasversion	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035975/pdf/	en_US
dash.license	LAA
dc.subject	JAK2	en_US
dc.subject	MPL	en_US
dc.subject	TET2	en_US
dc.subject	myeloproliferative	en_US
dc.title	IDH1 and IDH2 Mutation Studies in 1473 Patients with Chronic-, Fibrotic- or Blast-Phase Essential Thrombocythemia, Polycythemia Vera or Myelofibrosis	en_US
dc.type	Journal Article	en_US
dc.description.version	Version of Record	en_US
dc.relation.journal	Leukemia	en_US
dash.depositing.author	Wadleigh, Martha
dc.date.available	2011-09-21T14:51:19Z
dash.affiliation.other	HMS^Medicine-Brigham and Women's Hospital	en_US
dash.affiliation.other	HMS^Medicine-Brigham and Women's Hospital	en_US